Pune, Maharashtra, India, September 21 2022 (Wiredrelease) Prudour Pvt. Ltd –:Pfizer Inc. is a pharmaceutical powerhouse that has been in operation for over 150 years. The company has developed and manufactured some of the world’s most innovative and life-saving drugs. Pfizer’s products are available in over 150 countries, making it a truly global player in the pharmaceutical industry. Pfizer’s products touch the lives of millions of people around the world, and the company is committed to improving the lives of its patients through its innovative products and services. Pfizer Inc. is a global leader in the pharmaceutical industry, and its products have helped improve the lives of millions of people around the world. Its products include Lipitor (atorvastatin), Viagra (sildenafil), Celebrex (celecoxib), Lyrica (pregabalin), and Zoloft (sertraline).
It offers contract manufacturing services, sterile injection pharmaceuticals, biosimilars, active pharma ingredients (APIs), and sterile injectable pharmaceuticals. Pfizer sells its products via wholesalers and retailers, hospitals, clinics as well as government agencies, pharmacies, and clinics. It has manufacturing facilities in India and China as well as Germany, Singapore, Singapore, Italy, Belgium and Germany. It sells its products in North America and South America, Asia-Pacific as well as Australia, Europe, Africa, and the Middle East. Pfizer’s headquarters are located in New York, USA.
The company has a strong financial position, with revenues of $52.5 billion in 2016 and $48.8 billion in 2017. The net income was $10.4 billion in 2016 and $12.6 billion in 2017. The total assets were $191 billion in 2016 and $205 billion in 2017. The total equity was $70 billion in 2016 and $79 billion in 2017. Pfizer Inc.’s stock price has been on a gradual uptrend over the past five years, from around $20 per share in 2013 to its current level of around $36 per share.
Place a Direct Order Of Pfizer Inc Company Profile @ https://market.us/purchase-company/?company_id=80035
Key Financials Revenue (US$Mn)
– Pfizer Inc. generated US$ 81 288 Mn in annual revenue in 2021
– Pfizer Inc.’s 2020 annual revenue was US$ 41.908 Mn. This is a decrease of -19.02% from 2019.
– Pfizer Inc reported a -3.54% decline in annual revenue from 2018 to 2019, which amounts to US$ 51.750 Mn
– Pfizer Inc. generated total revenue of US$ 53 647 Mn in 2018.
Browse Full Summary of Pfizer Inc Company Profile@ https://market.us/company/pfizer-inc/
– Pfizer Inc.’s operating income in 2021 was US$ 22,235 Mn. This is a 130.99% rise over 2020.
– Pfizer Inc’s 2020 operating income was US$ 8,760 Million
– Pfizer Inc’s operating profit of US$ 13,921Mn, which was down -7.47%, was indexed in 2019.
– Pfizer Inc had an operating income in 2018 of US$ 15,045 Million
Pfizer Inc has been in the news recently for its involvement in the development of a coronavirus vaccine. The company is working with German biotech firm BioNTech to develop the vaccine. Clinical trials of the vaccine are currently underway. If the vaccine is successful, it could be available for use by the end of 2020. Pfizer Inc is also working on developing other potential treatments for coronavirus, including an antiviral drug and a monoclonal antibody treatment.
General Dynamics Corporation Company Profile Report: https://market.us/company/general-dynamics-corporation/
Northrop Grumman Corporation Company Profile Strategic Moves, and Competitive Intelligence Report – Market.us: https://market.us/company/northrop-grumman-corporation/
Thales S.A. Company Profile and News – Market.us: https://market.us/company/thales-s-a/
This content has been published by Prudour Pvt. Ltd company. The WiredRelease News Department was not involved in the creation of this content. For press release service enquiry, please reach us at contact@wiredrelease.com.
PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings. The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings. The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Copyright © 2022 PHARMIWEB.COM LIMITED, rights reserved by the relevant holders.
You are leaving PharmiWeb.com
Disclaimer: You are now leaving PharmiWeb.com website and are going to a website that is not operated by us. We are not responsible for the content or availability of linked sites.
ABOUT THIRD PARTY LINKS ON OUR SITE
PharmiWeb.com offers links to other third party websites that may be of interest to our website visitors. The links provided in our website are provided solely for your convenience and may assist you in locating other useful information on the Internet. When you click on these links you will leave the PharmiWeb.com website and will be redirected to another site. These sites are not under the control of PharmiWeb.com.
PharmiWeb.com is not responsible for the content of linked third party websites. We are not an agent for these third parties nor do we endorse or guarantee their products. We make no representation or warranty regarding the accuracy of the information contained in the linked sites. We suggest that you always verify the information obtained from linked websites before acting upon this information.
Also, please be aware that the security and privacy policies on these sites may be different than PharmiWeb.com policies, so please read third party privacy and security policies closely.
If you have any questions or concerns about the products and services offered on linked third party websites, please contact the third party directly.